ESR1 and breast cancer: Recent data by Metcalfe and colleagues also found worsened survival in ER-positive BC BRCA2 mutation carriers (the 20-year survival rate was 62.2% and 83.7% (p = 0.03) for ER-positive and ER-negative patients, respectively) [26].